The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences' magrolimab ... me" signal that prevents the cancer being attacked by white blood cells called macrophages.

That’s because it can increase the risk of blood clots or stimulate the growth of some cancer types ... will launch Veozah at a price of $550 per month, which is around three times the price ...